ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional Results available

A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure

ClinicalTrials.gov ID: NCT04988295

Public ClinicalTrials.gov record NCT04988295. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 10, 2026, 4:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure

Study identification

NCT ID
NCT04988295
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Janssen Research & Development, LLC
Industry
Enrollment
776 participants

Conditions and interventions

Interventions

  • Amivantamab Drug
  • Carboplatin Drug
  • Lazertinib Drug
  • Pemetrexed Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 16, 2021
Primary completion
Jul 9, 2023
Completion
Nov 29, 2027
Last update posted
May 7, 2026

2021 – 2027

United States locations

U.S. sites
28
U.S. states
17
U.S. cities
26
Facility City State ZIP Site status
Southern Cancer Center, PC Mobile Alabama 36608
Arizona Oncology Associates Tucson Arizona 85711
City of Hope Duarte California 91010
Cedars Sinai Medical Center Los Angeles California 90048
University of California Irvine Orange California 92868
Rocky Mountain Cancer Centers Colorado Springs Colorado 80907
Holy Cross Hospital - Michael and Dianne Bienes Comprehensive Cancer Center Fort Lauderdale Florida 33308
University Cancer And Blood Center LLC Athens Georgia 30607
University of Mississippi Medical Center Jackson Mississippi 39216
Nebraska Cancer Specialists Grand Island Nebraska 68803
Astera Cancer Care East Brunswick New Jersey 08816
TriHealth Network Cincinnati Ohio 45220
Providence Portland Medical Center Portland Oregon 97213
Kaiser Permanente Northwest Portland Oregon 97227
Alliance Cancer Specialists Horsham Pennsylvania 19044
University of Pittsburgh Medical Center Pittsburgh Pennsylvania 15232
Baptist Cancer Center Memphis Tennessee 38120
Texas Oncology-Medical City Dallas Dallas Texas 75230
Texas Oncology Baylor Charles A Sammons Cancer Center Dallas Texas 75246
Texas Oncology Grapevine Texas 76051
Oncology Consultants Texas Houston Texas 77030
Texas Oncology - Northeast Longview Texas 75601
University of Vermont Medical Center Burlington Vermont 05401
University of Virginia Charlottesville Virginia 22908
Virginia Cancer Specialists Fairfax Virginia 22031
Blue Ridge Cancer Care Wytheville Virginia 24382
NorthWest Medical Specialties, PLLC Puyallup Washington 98373
Compass Oncology Vancouver Washington 98684

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 221 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04988295, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 7, 2026 · Synced May 10, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04988295 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →